Helixgate https://validator.w3.org/feed/docs/rss2.html Terns rebuffed a higher bid before selling to Merck STAT+: States looking to regulate use of chatbots ARPA-H selects three teams in $100M effort to repair and regrow ailing joints Terns sold to Merck for 13% lower than pharma’s initial offer because of clinical data Autoimmune Disease-Related Inflammation Reduced with ENDOtollins Drug Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis STAT+: Pharmalittle: We’re reading about FDA backing domestic production, another Gilead deal, and more FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs BioNTech to shutter Singapore HQ after ‘comprehensive review’ Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say Opinion: STAT+: Former Geisinger CEO: U.S. health systems must replace huge numbers of people with AI  A star scientist showed that better genetics lessons could reduce racism. It was the death knell for his career High-content CRISPR activation screens identify synthetically lethal RNA-based mechanisms to sensitize cancer cells to targeted T cell cytotoxicity Home Microplastics in Human Bile Drive Mitochondrial Dysfunction and Senescence STAT+: Health insurers score major win with higher 2027 Medicare Advantage rates CRISPR at 25: The Past, Present, and Future of Genome Editing Immunotherapy Enhanced by Restoring Mitochondrial Function in Dendritic Cells Hims & Hers says limited data stolen in social engineering attack Proposed FDA budget sets Makary up to boost US biotech Amgen seeks to buoy Tepezza with injectable data in face of incoming competition STAT+: A key Medicare Advantage announcement is due today Machine Learning and Single-Cell Technology Combined to Drive High-Performance Cell Line Development Anthropic pays $400M for biotech; Praxis epilepsy drug hits in Phase 1/2 trial Takeda ends partnership with Denali amid restructuring STAT+: Pharmalittle: We’re reading about an FDA delay forcing a biotech to close, a Neurocrine deal, and more Pharma Pipeline Stalls for First Time in Decades: Citeline Nuclera launches GPCR-focused nanodisc panel  Nanotube Injector Boosts Mitochondrial Performance Through Cytoplasmic Transfer STAT+: Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal Neurocrine will pay $2.9B for Soleno and its Prader-Willi medicine Stipple Bio launches with $100M to find more precise targets on cancer proteins Perks persuade participants Opinion: ‘Medical nutrition’ helps keep my son, and many others, healthy. But insurance won’t cover it Biotech Looks to Replimune RP1 Decision as ‘First Indicator’ of FDA Direction AI model designs new treatment candidate for opioid addiction that cuts cravings in rats Pharma’s dealmaking tear; Blackstone raises record fund; Xolair energizes allergy research; and more  Gungnir codec enabling high error-tolerance and low-redundancy DNA storage through substantial computing power FDA Reversals in Rare Disease Space Highlight Confusion Around External Controls StockWatch: Price War Dampens Lilly Surge After Oral GLP-1 Wins FDA Nod Injectable Microgel Developed to Reduce Bleeding in Infants Undergoing Surgery Epigenetic Strategy Restores Tumor Suppressor in Acute Myeloid Leukemia Models STAT+: NIH would get $5 billion cut under Trump’s 2027 budget, but Congress unlikely to go along Trump revives pharma tariffs with 100% charges, but leaves loopholes STAT+: Up and down the ladder: The latest comings and goings White House floats 12.5% budget cut for HHS in FY2027, reiterates reorganization plan